Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
NCT ID: NCT01010217
Last Updated: 2020-03-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
176 participants
INTERVENTIONAL
2009-11-05
2017-10-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers will study the health status of these patients at 3 months after the transplant.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00006042
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
NCT00255710
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
NCT00423514
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
NCT02224872
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. This may cause the cancer cells to die.
In this study, researchers want to learn if cyclophosphamide can help to prevent graft-versus-host disease (GVHD -- when transplanted immune tissue, such as white blood cells, attacks the tissues of the recipient's body).
Melphalan, thiotepa, and fludarabine are commonly used in combination with a stem cell transplant.
Study Treatment Administration:
If you are found to be eligible to take part in this study, you will receive chemotherapy for 6 days:
* You will receive melphalan by vein over 30 minutes on Day -8 (8 days before the transplant).
* You will receive thiotepa by vein over 4 hours on Day -7.
* You will receive fludarabine by vein over 1 hour on Days -6, -5, -4, and -3.
If thiotepa is not available, you will receive melphalan by vein over 30 minutes on Day -6 and fludarabine by vein over 1 hour on Days -5, -4, -3, and -2. You will receive total body irradiation (TBI) on Day -1.
On Day 0, you will receive the donor's stem cells by vein. This may last anywhere from 15 minutes to several hours.
On Days 3 and 4, you will receive cyclophosphamide by vein over 3 hours. You will also receive mesna by vein over 30 minutes every 4 hours for a total of 10 mesna doses on Days 3 and 4. Mesna is given to lower the risk of side effects to the bladder.
Starting on Day 5, you will receive tacrolimus and mycophenolate mofetil (MMF) to help lower the risk of GVHD. Tacrolimus will be given by vein as a continuous infusion for about 2 weeks. After the 2 weeks of taking tacrolimus by vein, you will take tacrolimus by mouth as a pill for at least 3 months. MMF will be given by mouth, 3 times a day, usually until Day 35.
Starting on Day 7, you will receive filgrastim (G-CSF) once a day as an injection under the skin, until your blood cell counts reach a high enough level.
Depending on the type of disease that you have, your doctor may decide to give you rituximab by vein over several hours on Days -13, -6, 1, and 8. Rituximab is given to help the body get rid of abnormal white blood cells.
Length of Study Participation:
You will be in the hospital for about 4 weeks after the transplant. You will be taken off study if the disease gets worse. The study drugs will be stopped if intolerable side effects occur.
Follow-Up Visits:
You will be asked to stay close enough to Houston to be able to come back for any visits for at least 100 days after the transplant.
At 1, 3, 6, and 12 months after the transplant, the following tests and procedures will be performed:
* You will have a physical exam.
* Blood (about 4 tablespoons) will be drawn for routine tests.
* You will have a bone marrow biopsy/aspirate to check the status of the disease. If you have lymphoma or aplastic anemia, you may have a bone marrow biopsy/aspirate at 3, 6, and 12 months, if your doctor thinks it is needed.
* Blood (about 4 tablespoons) will be drawn to measure tumor cells and to predict graft failure and/or relapse.
* You may have urine collected and/or scans performed such as x-rays, CT scans, and/or a positron emission tomography (PET) scan. These scans and urine tests would only be done if the study doctor thinks they are needed to check the status of the disease.
* Blood (about 4 tablespoons) will be drawn to check your immune system.
If you have AML, at 2 months after the transplant, blood (about 4 tablespoons) will be drawn to check your immune system.
If you have MM, you will have a bone survey once a year.
If the study doctor thinks it is needed based on side effects you may be having, additional follow-up tests will be performed.
You may be contacted by phone 1-2 times a year to ask about the status of the disease. These calls will take about 10 minutes to complete.
This is an investigational study. All of the drugs used in this study are commercially available and FDA approved. However, it is investigational to give high-dose cyclophosphamide for preventing GVHD that may occur after a stem cell transplant from a tissue-mismatched donor.
Up to 337 patients will take part in this study. All will be enrolled at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Haploidentical related
Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m\^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m\^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
Cyclophosphamide
50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Fludarabine
40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
Melphalan
140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
Mesna
10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
Rituximab
CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
Stem Cell Transplantation
Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
Thiotepa
5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
Tacrolimus
0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
Mycofenolate mofetil
15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
G-CSF
5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
1 Antigen Mismatch Related or Unrelated
Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
Cyclophosphamide
50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Fludarabine
40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
Melphalan
140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
Mesna
10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
Rituximab
CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
Stem Cell Transplantation
Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
Thiotepa
5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
Tacrolimus
0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
Mycofenolate mofetil
15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
G-CSF
5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
Matched Unrelated Donor (MUD)
Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
Cyclophosphamide
50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Fludarabine
40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
Melphalan
140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
Mesna
10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
Tacrolimus
0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
Mycofenolate mofetil
15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
G-CSF
5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclophosphamide
50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
Fludarabine
40 mg/m\^2 IV over 1 hour on Days -6, -5, -4, and -3.
Melphalan
140 mg/m\^2 IV (or 100 mg/m\^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
Mesna
10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
Rituximab
CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
Stem Cell Transplantation
Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
Thiotepa
5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
Tacrolimus
0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
Mycofenolate mofetil
15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
G-CSF
5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery \> 1000/mcl.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Acute lymphocytic leukemia (ALL) in CR1 with high-risk features including adverse cytogenetics such as t(9;22), t(1;19), t(4;11), or MLL gene rearrangements; ALL in second or greater remission or ALL with relapsed disease, peripheral blood blasts \< 1000/microliter, ALL patients must show response to most recent received chemotherapy;
3. Acute myeloid leukemia (AML) in CR1 with intermediate-risk disease or high-risk features defined as: Greater than 1 cycle of induction therapy required to achieve remission; Preceding myelodysplastic syndrome (MDS) or myeloproliferative disease; Presence of FLT3 mutations or internal tandem duplications; FAB M6 or M7 classification; Adverse cytogenetics, -5, del 5q, -7, del7q, abnormalities involving 3q, 9q, 11q, 20q, 21q, 17, +8 \[\> 3 abnormalities\], peripheral blood blasts \<1000/microliter, AML patients must show response to most recent received chemotherapy;
4. AML in second or greater remission, primary induction failure and patients with relapsed disease, peripheral blood blasts \<1000/microliter; patients \> 55 years and \</= 75 years need to be in morphologic remission at transplant (\< 5% blasts).
5. Myelodysplastic syndrome (MDS) with International Prognostic Scoring System (IPSS) intermediate-2 or higher; or therapy-related MDS
6. Aplastic anemia with Absolute neutrophil count (ANC)\<1000 and transfusion dependent after they failed immunosuppression therapy
7. Chronic myeloid leukemia (CML) \>/=1st chronic phase, after failed \>/=2 lines of tyrosine kinase inhibitors; in accelerated or blast phase with \> 30% bone marrow blasts;
8. Prior allogeneic stem cell transplant more than 6 months from the first transplant, in remission.
9. Chemotherapy-sensitive relapsed lymphoma (Complete or partial response), Hodgkin's or non-Hodgkin's lymphoma, no evidence of "bulky" disease (\> 10 cm in diameter);
10. Patients with chemo-sensitive CLL with persistent or recurrent disease after fludarabine-based regimens, no evidence of "bulky" disease (\> 10 cm in diameter)
11. Patients with poor prognosis multiple myeloma by cytogenetics (del13, del 17p, t(1;14) or t(14;16) or hypodiploidy, with advanced disease (stage\>/=2) and /or relapsed after autologous stem cell transplant.
12. Patients with myelofibrosis (Lille \>0, transfusion dependency, progression to blast phase; however, in remission from AML) or chronic myelomonocytic leukemia (CMML). These patients will be treated with the reduced-intensity conditioning regimen #2 and will be subject to the same stopping rule as the group \>/= 55 years or with comorbidities.
13. Zubrod performance status 0-1 or Lansky PS greater or equal to 70%.
14. Patients above \>/=65 years old should have an age-adjusted co-morbidity index of \</= 3.
15. Available donor able to undergo a bone marrow harvest. For matched unrelated donor transplants only: Peripheral blood stem cells may be collected if donor is unavailable for bone marrow harvest or if adequate bone marrow cannot be collected.
16. Bilirubin \</= 1.5 mg/dl (unless Gilbert's syndrome), ALT or AST \</= 200 IU/ml.
17. Serum creatinine clearance \>/=50 ml/min (calculated with Cockcroft-Gault formula); Creatinine for children \</=1.5 mg/dl or \</=2 times upper limit of normal for age (whichever is less);
18. Diffusing capacity for carbon monoxide (DLCO) \>/= 45% predicted corrected for hemoglobin. For pediatric patients, if unable to perform pulmonary function, \>/= 92% oxygen saturation with pulse oximetry.
19. Left ventricular ejection fraction (LVEF) \>/= 40%.
20. Patient or patient's legal representative, parent(s) or guardian should provide written informed consent. Assent of a minor if participant's age is at least seven and less than eighteen years.
Exclusion Criteria
2. Patients with active infections. The PI is the final arbiter of the eligibility.
3. Liver cirrhosis with greater than grade 1 stage 1 inflammation/fibrosis
4. Uncontrolled central nervous system (CNS) involvement by tumor cells
5. Patients with AML must have less than 30% bone marrow blasts and no peripheral blood blasts.
6. History of another primary malignancy that has not been in remission for at least 3 years. (The following are exempt from the 3-year limit: non-invasive nonmelanoma skin cancer, fully excised melanoma in situ \[Stage 0\], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear.)
7. Positive Beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization.
8. Inability to comply with medical therapy or follow-up.
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefan Ciurea, MD
Role: STUDY_CHAIR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2011-03144
Identifier Type: REGISTRY
Identifier Source: secondary_id
2009-0266
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.